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Abstract  
 
Background: High quality leadership and chairing skills are vital for good performance in 
multidisciplinary tumor boards (MTBs), but no instruments currently exist for assessing and 
improving these skills.  
Objective: to construct and validate a robust instrument for assessment of MTB leading and 
chairing skills. 
Design and setting: We developed an observational MTB leadership assessment instrument 
(ATLAS). ATLAS includes 12 domains that assess the leadership and chairing skills of the 
MTB chairperson. ATLAS has gone through a rigorous process of refinement and content 
validation prior to use to assess the MTB lead by two urological surgeons (blinded to each 
other) in seven real-live (n=286 cases) and 10 video-recorded (n=131 cases) MTBs. 
Outcome measures and statistical analysis: ATLAS domains were analyzed via descriptive 
statistics. Instrument content was evaluated for validity using the Content Validation Index 
(CVI). Intraclass Correlation Coefficients (ICCs) were used to assess inter-observer 
reliability.  
Results: Instrument refining resulted in ATLAS including the following twelve domains: 
time management, communication, encouraging contribution, ability to summarize, ensuring 
all patients have treatment plan, case prioritization, keeping meeting focused, facilitate 
discussion, conflict management, leadership, creating good working atmosphere and 
recruitment for clinical trials. CVI was acceptable and inter-rater agreement adequate to high 
for all domains. Agreement was somewhat higher in real-time MTBs compared to video 
ratings. Concurrent validation evidence was derived via positive and significant correlations 
between ATLAS and an established validated brief MTB leadership assessment scale.  
Conclusion: ATLAS is an observational assessment instrument that can be reliably used for 
assessing leadership and chairing skills in cancer MTBs (both live and video-recorded). The 
ability to assess and feedback on team leader performance provides the ground for promotion 
of good practice and continuing professional development of tumor board leaders. 
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Summary: In this article, we developed a tool to scientifically assess the leadership and 
chairing skills in the cancer tumor boards. This tool offers an opportunity to assess leadership 
skills and capabilities within these boards, and take action to improve them accordingly 
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Introduction:  
Multidisciplinary tumor boards (MTBs; or ‘cancer conferences’) are well established in 
cancer care pathways in the UK for 2 decades (1, 2) and have been embraced in many other 
countries (3-6) as a standard practice to deliver cancer care. Inception of MTB-driven cancer 
care came about to ensure that cancer patients benefit from the expertise of a range of 
specialists for their diagnosis and treatment, and that care is provided according to standard 
guidelines. Emerging evidence shows that MTBs are associated with improved treatment 
decision-making(7, 8), and improved survival and reduction in unwarranted survival variation 
among hospitals.(9, 10)  
 
Although critical for the delivery of cancer care, there is currently no agreed way to evaluate 
MTBs.(5) In the UK, where they have a 20-year history, MTBs are subject to a quality 
assurance exercise, termed  the ‘cancer peer review’. This provides an annual mandatory 
mechanism for assessment of the MTBs against agreed standards; these incorporate the 
process and structural aspects of MTBs, such as team composition. Patient survival has been 
proposed as a quality metric, but is deemed an unsophisticated measure, in that it is far too 
multifactorial to be solely attributed to effective MTB working. Further, there is currently 
little evidence internationally regarding how to scientifically address the multiple ‘human 
factors’ that can and do affect the functionality of a MTB. These include elements such as 
team decision-making, quality of team interactions, and, crucially, quality of team leadership. 
Such ‘non-technical’ elements of team performance are critical for safe and effective care 
delivery in areas such as operating rooms, critical care and emergency medicine – yet they 
remain largely under-explored within the cancer setting.(11, 12) 
 
In this paper, we focus on leadership skills required for an effective MTB. No instrument to 
our knowledge currently exists that assesses leadership skills within the MTB with scientific 
accuracy and validity. Leadership can be defined as “a process of social influence through 
which an individual enlists and mobilizes the aid of others in the attainment of a collective 
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goal.(13) In MTBs, the role of leader, who commonly has the formal role of chairing the 
MTB, is central to effective running of the meetings. In a national survey of more than 2000 
specialist MTB members conducted in 2009 across all tumor types in the UK, 98% of the 
respondents agreed that good leadership is essential for productive teamworking.(14) Based 
on these data, the report ‘The Characteristics of an Effective Multidisciplinary Team’(15) 
summarized the key leadership skills required of an effective MTB leader. The leader has a 
unique role in the decision-making process in MTBs that is different from other team-
members – i.e., facilitating multidisciplinary team discussion and information sharing.  
Healthcare is traditionally hierarchical, hence a more autocratic leadership style tends to 
prevail where the leader derives their power from their  position of authority(16); however 
evidence from social sciences points to this being detrimental to team working and 
productivity.(17)The available evidence shows that the most effective leadership is 
democratic where the leader successfully sets goals and influences team to achieve them by 
working with the team in a collaborative and cooperative manner thus facilitating 
multidisciplinary contributions to case-discussion and information sharing.(13, 17)  
 
Grounded on the above evidence base, the aim of this study was to scientifically develop and 
evaluate an instrument to systematically evaluate leadership skills at MTBs.  
 
Methods 
We developed ‘A Tumor Leadership Assessment inStrument’ (ATLAS) using state-of-the-art 
psychometric science. Tool development proceeded in phases, as illustrated in Figure 1. 
 
………………. 
Figure 1 
……………….. 
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Phase 1: Initial instrument derivation  
As per standard practice,(18) instrument content was informed by (i) evidence on the 
characteristics of effective MTB leadership, (ii) expert input from senior MTB specialists, 
including current/former team leaders, and (iii) critical review from a human factors specialist 
with more than 10-years-experience in evaluating leadership and team skills in surgical and 
cancer pathways (NS) and a senior Attending-level surgeon/team leader/former national lead 
for MTB development in England (JSAG). This initial process resulted in 14 key leadership 
elements, which were subsequently refined.  
 
Phase 2: ATLAS content validation  
Content validation (to ensure the content of the evaluation is appropriate for its purpose) was 
undertaken in 2 stages: 
 
Stage 2.1: The initial ATLAS instrument was independently and blindly reviewed by 10 
senior MTB specialists who regularly chair their own MTBs. As per their recommendations, 
instrument wording and content was refined, resulting in 12 revised leadership domains for 
further assessment.  
 
Stage 2.2: The resulting instrument was submitted to a quantitative content validation 
procedure. An online survey of a national sample of urology MTB specialists attending the 
Prostate Cancer UK Summit in 2013 was carried out. Participants were asked to rate 
individual leadership domains on 5-point Likert scales (1=Not applicable to 5=Extremely 
important). Based on the survey, a quantitative Content Validity Index (CVI) was calculated 
for each instrument item.(19) A CVI represents the proportion of experts who rated an item 4 
or 5 on the 5-point content validation scale of its importance for MTB leadership.(20) Higher 
CVIs indicate higher inter-expert agreement that an item is an important element and hence 
should be retained to evaluate the MTB leader. A CVI value of 0.78 is considered as 
minimum acceptable score.(21) 
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Phase 3: ATLAS reliability analyses  
A number of MTB leaders were assessed by two surgeon evaluators, trained in observational 
assessment (RJ, WA) using ATLAS. The 2 assessors were kept blinded to each other’s ratings 
throughout the assessment process to minimize the risk of bias. Leadership was evaluated in 
17 MTBs where 417 patients were reviewed (7 in vivo, 286 urologic cases; 10 video-
recorded, 131 cases across different tumors). The real time assessments were conducted in 
London NHS Hospitals and the videos used were of MTBs across different Hospitals in the 
United Kingdom. A score of 1-5 assessing leadership/chairing skills during the MTB was 
given by the evaluators against each individual criterion listed in ATLAS – such that the 
minimum score on the scale was 12 (representing poor chairing and leadership skills) and the 
maximum score was 60 (representing very effective chairing and leadership skills). Inter-rater 
agreement in scoring was subsequently assessed statistically.  
As part of the reliability analysis of the instrument, the internal consistency among the 
domains of the instrument was assessed using Cronbach’s alpha. 
 
Phase 4: ATLAS construct validation 
Modern psychometric theory requires that new instruments be subjected to a validation 
process through demonstrating their ‘relationships with other variables’.(22) This form of 
validity ensures a systematic, hypothesis-driven quantitative approach. For ATLAS validation 
we tested the following hypotheses: 
H1: ATLAS will correlate positively with existing scales assessing leadership elements 
within MTBs. 
H2: ATLAS will not correlate significantly or will correlate weakly with existing scales 
assessing other elements of MTB working. 
Positive evidence for both hypotheses needs to be provided to offer strong convergent (H1) 
and discriminant (H2) validation evidence. This will mean that ATLAS captures accurately 
leadership elements, and it is specific to those.  
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To carry out this validation and test the 2 hypotheses, we administered ATLAS concurrently 
with a pre-existing, well-validated global MTB team functioning assessment instrument that 
we have developed, the MTB-Metric for the Observation of Decision-making (MTB-
MODe).(11) MTB-MODe scores on 5-point behaviorally anchored scales (i) the quality of 
information presented at the MTB meeting when a case is reviewed and (ii) the quality of 
individual team-member’s contribution to team decision-making, including the team 
leader/chair. MTB-MODe is thus much broader than ATLAS. If ATLAS accurately captures 
leadership skills, it should show stronger correlations with the team leader/chair item of 
MTB-MODe and weaker (or no) correlations with the other MTB-MODe items.  
 
Analysis 
All ATLAS scores were analyzed via descriptive statistical analyses. Content Validation 
Indices (CVIs) for ATLAS domains were calculated from the survey responses.  Intraclass 
Correlation Coefficients (ICCs) were used to assess inter-rater agreement.(23, 24) Cronbach’s 
alpha was used to assess the internal consistency across the instrument domains. Alpha values 
of >0.70 are considered satisfactory.(25) Pearson’s correlation was used to test the 2 
validation hypotheses. Statistical analysis was conducted using SPSS version 20.0 (SPSS Inc., 
Chicago, IL). For all analyses significance was set at p<0.05.  
 
 
 
Results:  
Instrument domain derivation 
The initial 14 domains included in ATLAS (figure 2) were refined in phase 2.1 to 12 (figure 
3). 
 
………………. 
Figures 2 and 3 
……………….. 
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Instrument content validation and internal consistency 
Overall, 144 attendees responded to the online survey to validate the content of the instrument 
(Surgeons n=47, Nurses n= 37, Oncologists n=34, Radiologists n=24, others n=2). 68% 
(n=71) of the physicians were Attendings. 70% (n=101) of the respondents reported spending 
≥ 2 hours per week attending MTBs, with 16% (n=23) being the leaders of their MTB at the 
time of the study. Nearly half of the respondents practiced in specialist cancer centers (48%, 
n=70), 36% (n=52) of them in non-specialist hospitals, and the remaining 16% (n=23) 
practiced in both. The majority of the participants (n=82 answered this question) reported that 
their MTBs are led/chaired by surgeons (76%, n=62), with oncologists the second most 
frequent specialists in leadership role (18%, n=15). 
 
Table 1 summarizes the results of the formal content validation, showing the CVI for each 
scale item. The CVI represents the proportion of experts who rated the item as a 4 or 5 on a 5-
point scale – i.e., considered it critical component of leadership. All CVIs are above the cut-
off of 0.78, thus suggesting good content coverage.  
 
…………………… 
Table 1  
……………………. 
 
Further, in order to assess internal consistency of ATLAS, Cronbach’s alpha was calculated 
and showed a significant consistency at 0.80. This means that the 12 elements of the 
instrument tend to be scored in the same direction – which suggests good consistency in the 
overall instrument scoring.(25) 
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Inter-observer reliability in instrument usage  
Inter-rater agreement (in the form of ICCs) ranged 0.68-0.91 in the in vivo assessments 
compared to 0.65-0.88 for the video recorded MTB assessments. Overall, agreement was 
higher in meetings scored in real-time compared to those scored retrospectively based on 
video-recordings – the ICCs between the 2 blinded assessors showed this pattern in 7 out of 
the 12 elements of the scale. 
 
Correlational analyses – convergent & discriminant validation 
To further validate the instrument via the testing of the two proposed hypotheses, ATLAS 
scores were correlated with the mean global MODe scores on team functioning, and with the 
MODe Chairing component (i.e., the chair’s contribution to the MTB as measured by 
MODe). There was a significant positive correlation between ATLAS and MODe chairing 
scores (r=0.617, p=0.014) and a non-significant correlation between ATLAS and MODe 
global scores (r=-0.196, p=0.483), Table 2. These data support both our validation 
hypotheses, H1 and H2 and show that ATLAS capture leadership-specific skills at MTBs.   
………………. 
Table 2 
……………….. 
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Discussion: 
This is the first study to our knowledge to develop and evaluate an instrument to assess 
leadership skills within MTBs. The process and the steps of the instrument development 
ensure that the ATLAS instrument is both scientific and relevant to users. Our study relied on 
evidence and also experts to produce the content of the instrument. The final version of the 
instrument showed content validity and internal consistency. The assessors statistically agreed 
on ratings of leadership and chairing characteristics. Reliable assessment was demonstrated 
for all the 12 domains of the instrument in both real-time MTB meeting assessments and 
video–recorded MTBs. Finally, ATLAS showed validation evidence through statistical 
analyses of its relationship with other relevant variables as per requirement of modern 
psychometric theory.  
 
To-date, evidence looking at leadership and chaining in multidisciplinary tumor board teams 
is anecdotal. Several authors have discussed the attributes and characteristics of a good and 
effective MTB lead – including the ability to encourage full participation of all team members 
and good communication skills. (31, 32) In a national survey in the UK of more than 2000 
MTB members, the majority of respondents listed non-technical skills such as assertiveness, 
good communication skills and being a team player, and a minority listed clinical or technical 
expertise as a quality on the qualities that make a good and effective MTB chair/lead. (14) 
Currently chairs or leaders of MTBs are often senior clinicians, the majority being surgeons. 
If, however, non-technical skills are considered to be more essential in chaining and leading 
such complex meetings than clinical expertise, it may not be necessary or indeed beneficial 
for surgeons to be leading MTBs. Innovative senior cancer nurses are leading teams and 
chairing MTBs in some UK cancer centers (33) and perhaps non-clinical staff or former users 
of the services could also be contemplated for this role if they have the requisite chairing and 
leadership skills. Such innovative practices may help address some of the shortcomings of 
MTB-based decision-making, which include the lack of focus on the psychosocial and 
holistic patient review and the often exclusive focus on the biomedical aspects of the disease. 
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(8,34) Viewing leadership of a MTB as a skill-driven task, rather than one allocated by 
clinical seniority, has the potential to improve the flow and widen and focus of MTBs.       
 
The study has limitations. The survey sample was a sample of convenience consisting of 
attendees of the Prostate Cancer UK summit workshop.  The survey developed via 
SurveyMonkey engine was distributed to the meeting delegates. The authors did not 
have access to the full delegate list; hence response rate could not be reported. This does 
mean there is an element of self-selection, likely due to their interest in the topic of the 
survey, however the number of respondents (68% consultants/attendings) and the 
geographical distribution of the sample offer national coverage. There was a discrepancy of 
the ICC (reliability) between the real-time and video-recorded MTB assessment. This perhaps 
can be partly explained by that the videos were not recorded for this purpose and the quality 
of sound in some videos was not ideal. Finally the 12 domains of the instrument represent the 
items that are reported in the limited literature about the desired criteria of an effective MTB 
leadership; however a larger scale study is needed to find out if there are other criteria that 
could potentially also contribute to effective chairing and leadership and thus ATLAS can be 
further improved.   
Urological surgeons were selected to evaluate the MTB chair using the developed instrument 
was based on availability of those MTB members, however we expect similar results by other 
trained MTB members. 
 
We consider ATLAS a potentially useful instrument to help improve the flow of MTBs and 
the team-decision-making that takes place within them. Currently, MTBs suffer from time 
pressure and variability in the quality of decision-making.(11, 34) The MTB clinical lead who 
is often the chairperson too, is expected to play a key role in the functioning of the meeting 
and in ensuring the meeting is fit for its purpose – including MTBs are run in a time-efficient 
manner whilst taking into account the views of all the available experts in order to formulate a 
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decision plan that is based on evidence. In reality, these senior clinicians (often surgeons) are 
commonly left unsupported in this role. ATLAS offers a valid framework to begin analyzing 
how best to support the leadership of MTBs. As it stands, ATLAS can offer a means to 
evaluate MTB running and offer near real-time feedback to team leaders. It also identifies in a 
valid and meaningful manner the type of skills MTB leadership involves. We propose that 
ATLAS be used as a map of the nontechnical skills necessary for effective clinical leadership 
in the cancer care setting, and applied as a self-assessment and improvement tool by MTBs. 
The ATLAS assessment tool is not believed to require significant training. However if 
ATLAs is to be used to appoint, for example, team leads in a formal process then perhaps 
a formal assessors calibration phase is required. Having an efficient MTB leader is vital 
for effective decision making in the MTB, however, the presence of all the key MTB 
members is the meeting is as important. 
 
Conclusions: 
We developed an instrument to scientifically capture leadership and chairing skills in the 
cancer MTB setting. ATLAS showed good evidence for reliability and validity when tested 
across different tumors and cancer teams. ATLAS offers an opportunity to assess leadership 
skills and capabilities within MTBs, and take action to improve them accordingly.  
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Figure 1 diagram detailing the steps of ATLAS validation process. 
 
Initial instrument derivation 
 
(14 leadership elements) 
 
ATLAS content validation 
 
 
 
 
 
 
 
 
 
 
 
ATLS reliability analysis 
 
 
 
 
 
 
ATLAS construct validation (correlation with the a validated tool MODE) 
 
 
 
 
 
Review by 10 senior MTB 
specialists (as a result the 
tool was refined to 12 
Leadership elements) 
 
Quantitative content validation 
(via a survey of 144 specialists 
attended the prostate cancer 
UK summit in 2013) 
 
Real time assessment 
of urology MTBs 
 
Assessment of recoded 
MTBs( various specialties) 
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Figure 2. The initial ATLAS instrument 
How would you rate the MTB Chair on the following scale? 
 
 
Chairing Criteria Rating 
1. Ensure the meeting runs to time           1             2             3             4             5 
2. Communication           1             2             3             4             5 
3. Allowing/encouraging all team 
members to contribute ( team working) 
          1             2             3             4             5 
4. Ability to summarize            1             2             3             4             5 
5. Time keeping (all patients discussed)           1             2             3             4             5 
6. Each patient discussed has a clear 
treatment plan 
          1             2             3             4             5 
7. Keeping meeting focused           1             2             3             4             5 
8. Facilitate discussion           1             2             3             4             5 
9. Conflict resolution            1             2             3             4             5 
10. Leadership           1             2             3             4             5 
11. Creating a good working atmosphere           1             2             3             4             5 
12. Constructive and fair to the team.           1             2             3             4             5 
13. Development of the MDT and its 
activities 
          1             2             3             4             5 
14. Team training needs are identified           1             2             3             4             5 
 
 
 
 
 
 
 
 
19 
 
Figure 3: The revised ATLAS instrument 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 																 															A Tumor Leadership Assessment inStrument’ (ATLAS) 													 	
Please	read	the	following	list	of	specifications	carefully	and	evaluate	them	accordingly																																																																																																																																Your	Specialty	and	Grade:			
																																																																																																																																																																																																																																																																																										Number	of	Years	of	Experience:																																																																														
Please	use	the	1-5	scale	to	evaluate	the	domains.	Please	provide	answers	for	all	domains	below.	
	
Chairing	criteria	 1	 2	 3	 4	 5	
1. Time	management	(all	patients	discussed)	 Meeting	started	15	minutes	late.	2	or	more	
cases	deferred	due	to	time	mis-management.	
	 Meeting	started	10	minutes	late.	1	
case	differed	due	to	time	mis-
management.	
	 Meeting	started	on	time.	No	patients	deferred	due	
to	time.	Chair	acknowledges	the	time.	
2. Communication	and	listening	 Poor-	detrimental	effect	to	function/efficiency	of	
MDT	meeting	
	
	 Neither	enhanced	nor	detracted	from	
function	
	
	 Effective	skills	
3. Allowing/encouraging	all	team	members	to	
contribute	(team	working)	
Does	not	invite	nor	give	a	space	to	members	to	
participate.	
	 Invites	or	gives	a	space	to	only	few	
members	to	participate.	
	
	 Invites	and	gives	space	for	members	to	participate.	
4. Ability	to	summarise	cases	using	the	
information	that	emerged	during	discussion.	
Not	summarising/cases	left	unclear.	 	 Summarised	some	cases.	Still	few	
cases	remained	unclear	
	 All	cases	that	were	unclear/inappropriately	
presented	were	accurately	summarised.	
5. Each	patient	discussed	has	a	clear	treatment	
plan	
No	clear	decision	for	many	patients	 	 Some	decision	plans	remained	
unclear.	
	 Unclear	plans	were	clarified.	Gives	clear	closure	to	
unclear	plans.	
6. Case	prioritisation	 Cases	were	not	prioritised.	 	 Attempts	to	prioritise	but	
inconsistent	or	ineffective.	
	
	 Cases	were	prioritised	as	necessary.	
7. Keeping	meeting	focused	(managing	
distractions)	
Distractions	affected	the	meeting/no	attempt	to	
keep	team	focused.	
	 Some	effort	to	refocus	the	team,	but	
not	consistent	
	 Refocuses	the	group	straight	away	when	team	
distracted.	Keeps	team	to	task.	
8. Facilitate	discussion	 Not	facilitating	discussion	when	needed.	Leads	
to	dysfunctional/unproductive	conversation.	
	 Attempts	to	facilitate	but	not	always	
effective.	
	
	 Effective	facilitation	of	discussion	and	decision	
making.	
9. Management	of	disruptive	personalities	
and/or	conflict	
Conflicts	remained	unsolved	or/and	difficult	
personalities	dominate/derail	meeting.	
	 Attempts	to	resolve	conflicts	but	
affected	/delayed	the	meeting.	
	 Effectively	resolves	conflicts	in	a	timely	manner.	
Allows	effective	decision	despite	conflict.	
10. 	Leadership	 Poor	leadership.	It	was	not	obvious	who	was	
leading	the	team.	
	 Some	but	inconsistent	or	ineffective	
leadership	skills.	
	
	 Effective	leadership.	Clear	who	chairs	the	team.	
Inspirational,	enthusiasm	for	service	
11. Creating	a	good	working	atmosphere	 Poor	atmosphere/climate	during	the	meeting.	
Unproductive,	antagonistic.		
	 Atmosphere	and	team	climate	mostly	
OK,	with	occasional	friction	
	 Very	good	atmosphere	and	team	climate	directly	
facilitated	by	the	Chair	
12. Recruitment	for	clinical	trials	 Most	eligible	patients	were	not	identified.	 	 Some	eligible	patients	were	
considered	for	trials.	
	 Ensured	that	eligibility	for	relevant	trials	
recruitment	is	considered	for	all	eligible	patients	
discussed.	
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Table 1. Content Validity Indices for all leadership components 
Items  
Number of respondents who rated 
the items as 5 (Extremely 
important) or 4 (Important) (n) 
Total 
Responses 
(n)* 
         
 
 
CVI 
Team working 116 116 1.00 
Communication 116 117 0.99 
Time management 114 116 0.98 
Ensure clear treatment plans 115 117 0.98 
Keeping meeting focused 113 116 0.97 
Ability to summarize 110 117 0.94 
Facilitate discussion 108 115 0.94 
Conflict management 103 114 0.90 
Leadership 103 115 0.90 
Creating good work 
environment 
106 115 0.92 
Case prioritization 95 115 0.83 
Recruiting for clinical trials 89 112 0.80 
Note. N = 144. CVI = Content Validation Indices. n = number of responses within each 
subgroup. 
*Respondents skipped questions in the survey hence the total responses is not equal 
throughout different domains. 
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Table 2. Overall correlations between ATLAS and MODe instruments (*p<0.05)  
 
  Mean 
score 
ATLAS  
 
(global 
scores)  
Mean 
score 
MTB-
MODe 
(global 
scores) 
Mean score 
MTB-MODe  
 
 
(chairing 
element scores) 
Mean score 
ATLAS  
(global scores) 
Pearson 
Correlation 
1 -0.196 0.617* 
N 15 15 15 
Mean 
score MTB-
MODE  
(global scores) 
Pearson 
Correlation 
 1 0.207 
N   15 
 
 
